Phenytoin Phil

The story

Phil has been seizure-free on phenytoin for a year. At his checkup his eyes beat side to side when he looks left, his gait is unsteady, his gums are swollen over his teeth, and his level is 26 mcg/mL.

Phil is a retired watchmaker renowned for his steady hands and his ability to make the tiniest adjustment to a mechanism without ever overcorrecting and throwing the whole timepiece out of balance. That same need for exquisitely precise, narrow adjustment defines his own treatment after Phil is diagnosed with epilepsy and started on phenytoin, an antiseizure medication that stabilizes overactive neuronal membranes by blocking sodium channels. Phenytoin has an unusually narrow therapeutic index, meaning the difference between a dose that controls Phil's seizures and a dose that produces dangerous toxicity is remarkably small, much like the fine tolerances Phil once worked with inside a watch mechanism. Small changes in his dose, his absorption, or even how well he shakes his oral suspension before measuring it can push his level from safely therapeutic into a toxic range with surprising speed.

Phil's neurologist establishes his target phenytoin level between 10 and 20 micrograms per milliliter, and for over a year he remains beautifully controlled with only rare breakthrough seizures. His wife proudly notes that his hands, once occasionally interrupted by seizure activity, have become as steady as they were during his watchmaking days. Phil takes his oral suspension form of the medication faithfully, though he has recently grown a bit careless about thoroughly shaking the bottle each time, assuming the liquid inside is uniformly mixed regardless of how vigorously he swirls it, a small shortcut that steadily begins concentrating more of the active drug toward the bottom of the bottle with each passing dose.

Over several weeks, Phil's wife notices he seems increasingly unsteady on his feet, occasionally stumbling while walking to the mailbox, and his speech has developed a subtle slur she initially attributes to fatigue. At his next follow-up appointment, the nurse performs a quick bedside neurological check and observes clear nystagmus, an involuntary rhythmic eye movement, along with mild ataxia when Phil attempts to walk heel-to-toe. His stat phenytoin level returns at 26 micrograms per milliliter, well above the therapeutic ceiling of 20. The nurse also notes, on closer examination of his mouth, that his gums have become visibly overgrown, partially covering the crowns of his lower teeth, a separate but well-known long-term effect of phenytoin therapy that had developed gradually and unnoticed over many months.

The nurse immediately reports the elevated level and neurological findings to the neurologist, who orders a temporary dose reduction rather than abrupt discontinuation, since stopping phenytoin suddenly risks precipitating status epilepticus. She reviews with Phil and his wife the critical importance of shaking the oral suspension thoroughly and consistently before every single dose, explaining that inconsistent mixing likely caused the rising toxic level. She also reinforces daily brushing, flossing, and regular dental visits to manage his gingival hyperplasia, and discusses the classic association between phenytoin and folate deficiency, coordinating supplementation as appropriate. She schedules follow-up levels to confirm his dose reduction successfully brings him back safely within the 10 to 20 range.